The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Long Islanders suffering from sleep apnea inundated the sleep center at St. Charles Hospital in Port Jefferson with phone ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter ...

Trump administration officials are making statements that some advocacy and medical groups say depict patients and the ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly , ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

Eli Lilly ( LLY -0.24%) has been a terrific investment in recent years. Thanks to significant clinical progress and outstanding financial results, the company has become the largest healthcare player ...

Chief financial officer Karsten Munk Knudsen said that the pharma giant's cash channel was key to regaining market share and ...